Literature DB >> 11397880

Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method.

H Leslie1, C H Courtney, P M Bell, D R Hadden, D R McCance, P K Ellis, B Sheridan, A B Atkinson.   

Abstract

PRL exists in different forms in human serum. The predominant form is little PRL (molecular mass 23 kDa) with smaller amounts of big PRL (molecular mass 50--60 kDa) and at times big big or macroprolactin (molecular mass 150--170 kDa). The frequency and clinical consequences of macroprolactinemia have not been clearly established, mainly because of difficulty in identifying these patients biochemically. This previously required the use of gel filtration chromatography, which could not be used routinely. Recently, a screening test using polyethylene glycol (PEG) has been used to identify macroprolactin in serum. Consequently, this study was designed to examine the use of PEG precipitation in the identification of patients with a predominance of macroprolactin and to establish the clinical characteristics of such a cohort. Over 12 months, 18,258 requests for serum PRL were received and of these 1225 patients had a serum PRL more than 700 mU/L. A total of 322 of these patients (26%) had a percentage recovery after PEG precipitation of less than 40%, thus indicating the presence of a predominance of macroprolactin. Fifty-five of these patients were referred for detailed clinical assessment. Symptoms typical of hyperprolactinemia were not common in this cohort. None had sustained amenorrhea and eight have had oligomenorrhea at age less than 40 yr. One had galactorrhea. All had pituitary imaging, and four had a microadenoma with none having a macroadenoma. PEG precipitation allows easy identification of macroprolactin in routine clinical practice. As the clinical consequences of this entity at this stage seem relatively benign, referral and intensive investigation of these patients may not be necessary. However, follow-up of a large cohort is required to ensure that the long-term outlook is likewise benign. This would have important implications for both patients and healthcare systems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11397880     DOI: 10.1210/jcem.86.6.7521

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

Review 1.  ACP best practice no 170. Investigation of infertility with the emphasis on laboratory testing and with reference to radiological imaging.

Authors:  C Williams; T Giannopoulos; E A Sherriff
Journal:  J Clin Pathol       Date:  2003-04       Impact factor: 3.411

2.  Prevalence of pituitary adenomas in macroprolactinemic patients may be higher than it is presumed.

Authors:  Gonca Tamer; Ayşegül Telci; Meral Mert; Ayse Kubat Uzum; Ferihan Aral; Refik Tanakol; Sema Yarman; Harika Boztepe; Nese Colak; Faruk Alagöl
Journal:  Endocrine       Date:  2011-09-30       Impact factor: 3.633

Review 3.  Long-term management of prolactinomas--use of long-acting dopamine agonists.

Authors:  David M Cook
Journal:  Rev Endocr Metab Disord       Date:  2005-01       Impact factor: 6.514

4.  Prevalence and reproductive manifestations of macroprolactinemia.

Authors:  Amanpreet Kaur Kalsi; Ashutosh Halder; Manish Jain; P K Chaturvedi; J B Sharma
Journal:  Endocrine       Date:  2018-09-29       Impact factor: 3.633

Review 5.  Neuroendocrine causes of amenorrhea--an update.

Authors:  Lindsay T Fourman; Pouneh K Fazeli
Journal:  J Clin Endocrinol Metab       Date:  2015-01-12       Impact factor: 5.958

6.  Clinical and radiological findings in macroprolactinemia.

Authors:  Serhat Isik; Dilek Berker; Yasemin Ates Tutuncu; Ufuk Ozuguz; Ferhat Gokay; Gonul Erden; Hatice Nursun Ozcan; Ferit Kerim Kucukler; Yusuf Aydin; Serdar Guler
Journal:  Endocrine       Date:  2011-12-21       Impact factor: 3.633

7.  Macroprolactinemia in hyperprolactinemic infertile women.

Authors:  Krithika Thirunavakkarasu; Pinaki Dutta; Subbiah Sridhar; Lakhbir Dhaliwal; G R V Prashad; Shalini Gainder; Naresh Sachdeva; Anil Bhansali
Journal:  Endocrine       Date:  2013-03-30       Impact factor: 3.633

8.  Identification of IgG-immunocomplex macroprolactin with an immunometric "sandwich" system: technical and clinical considerations.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; A Valentini
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  Macroprolactinemia: predictability on clinical basis and detection by PEG precipitation with two different immunometric methods.

Authors:  P Amadori; C Dilberis; A Marcolla; M Pinamonti; P Menapace; F Dal Bosco
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

10.  Hyperprolactinemia in asymptomatic patients is related to high molecular weight posttranslational variants or glycosylated forms.

Authors:  M Guitelman; M E Colombani-Vidal; C C Zylbersztein; L Fiszlejder; M Zeller; O Levalle; H E Scaglia
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.